• Skip to main content
  • Skip to footer
UK Plans to phase out animal testing cnb1662_ec-reg-news_navigation-ad_v2
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Products
    • PhysioMimix® Core Microphysiological System
    • Consumables
      • PhysioMimix® Multi-chip plates
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Discover the applications


Investigate the validated core application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix Core

cnb1476_physiomimix-core_mark_mocks_system_v2
Learn more

Consumables

Multi-chip plates
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Organ-on-a-Chip Resources

Featured

Resource image

Webinars

Building confidence for regulatory decision-making with immune competent models

Webinar Series 9 Episode 2

Discover how human liver models are building regulatory confidence in DILI risk assessment. How a continuously perfused, primary human Liver model, with immune-competent capabilities, can be leveraged to address a critical unmet need — capturing immune mediated toxicities associated with new drug modalities such as monoclonal antibodies (mAbs).

Read More
Resource image

Webinars

Building better data packages: The role of MPS in modern efficacy, toxicity and ADME workflows

Technology Network: Organoids and Microphysiological Systems Symposium 2026

Explores how MPS can be integrated into modern drug discovery workflows alongside other in vitro, in vivo and in silico tools to generate more predictive, human‑relevant data, improving translational confidence and informing decision making.

Read More
Resource image

Blogs

Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies

Knowing a drug’s bioavailability during lead optimization is crucial as it directly influences dosing strategy, therapeutic efficacy, safety margins, and formulation design.

Read More

Filters

Topic Area:
Resource Type:
Filter
Resource image

Whitepaper

A technology guide to assessing liver safety with microphysiological systems

Resource image

Webinars

Building confidence for regulatory decision-making with immune competent models

Resource image

Posters

Recapitulating Immune-Driven Hepatotoxicity Using a Liver Microphysiological Platform

Resource image

Blogs

Why the FDA animal testing phase-out for monoclonal antibodies?

Resource image

Blogs

Microphysiological systems for mAbs development: how do they address animal limitations?

Resource image

Webinars

Beyond hepatotoxicity red flags

Resource image

Brochures & Flyers

Organ-on-a-chip Contract Research Services Brochure

Resource image

Application notes

Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury

Resource image

Scientific publications

Gut-Liver Physiomimetics Reveal Paradoxical Modulation of IBD-Related Inflammation by Short-Chain Fatty Acids

Resource image

Scientific publications

Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation

Resource image

Videos and animations

Predicting the future: humanised drug evaluation testing using organ-on-a-chip technology

Resource image

Scientific publications

Integrated gut and liver microphysiological systems for quantitative in vitro pharmacokinetics studies

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • CN Bio awarded Innovate UK grant to reduce animal use in pharmacokinetic studies August 12, 2026
  • Organ-on-a-chip trends shaping the next phase of human-relevant R&D from the MPS World Summit 2026 July 6, 2026
  • Which microphysiological system contexts of use are aligned with regulatory roadmaps? June 2, 2026
Cyber Essentials Logo

Modal Title